Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical (Nasdaq: COLL) has announced a definitive agreement to acquire Ironshore Therapeutics for $525 million in cash, with a potential additional $25 million commercial milestone payment. This acquisition will expand Collegium's portfolio into neurology, specifically the ADHD market, through Ironshore's product Jornay PM. Key highlights include:
- Jornay PM's H1'24 prescriptions grew 32% year-over-year
- The transaction is expected to be immediately accretive to adjusted EBITDA
- Acquisition funded by cash on hand and new five-year financing
- Collegium estimates Q2'24 Pain Portfolio Net Revenue of $145 million, up 7% year-over-year
- The deal is expected to close in Q3 2024, subject to regulatory approvals
This strategic move aligns with Collegium's mission to build a diversified specialty pharmaceutical company, leveraging its commercial capabilities in a new market.
Collegium Pharmaceutical (Nasdaq: COLL), a diversified specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET following the release. Investors can access the call by dialing (877) 407-8037 (U.S.) or (201) 689-8037 (International) and referencing the "Collegium Pharmaceutical Q2 2024 Earnings Call." An audio webcast will be available on the company's website, with a replay accessible approximately two hours after the event.
Collegium Pharmaceutical has announced that the FDA has granted a six-month pediatric exclusivity extension for its Nucynta Franchise. This extension extends Nucynta's exclusivity to January 3, 2027, and Nucynta ER's exclusivity to December 27, 2025. The FDA had previously granted New Patient Population exclusivity for Nucynta in pediatrics, extending it until July 3, 2026. This extension is seen as a value enhancement for the Nucynta franchise, which is used for managing severe acute and persistent pain in both adults and pediatric patients. Collegium's Chief Medical Officer, Thomas Smith, highlighted the significance of this development for the company's near-term outlook and commitment to supporting patients with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the Jefferies Global Healthcare Conference in New York, NY, on June 5-6, 2024. The company's management will engage in a fireside chat on June 5, 2024, at 9:30 a.m. ET. The event will be webcast live and available on Collegium's Investors section. Additionally, a replay of the webcast will be accessible for 90 days post-event.
Collegium Pharmaceutical, Inc. announced a $35 million Accelerated Share Repurchase (ASR) program with Jefferies to buy back common stock as part of a $150 million repurchase program. The company aims to enhance shareholder value by leveraging its capital deployment strategy. The ASR agreement will result in Collegium receiving 888,889 shares initially, with the final number based on stock prices during the term.
Collegium Pharmaceutical, Inc. reported strong Q1 2024 financial results, including a net revenue of $144.9 million, record Belbuca® revenue of $50.7 million, and GAAP net income of $27.7 million. The company achieved a 5% increase in Adjusted EBITDA, authorized a $35.0 million share repurchase program, and reaffirmed its full-year 2024 guidance. Collegium also announced an authorized generic agreement with Hikma and a leadership transition. Financially, the company showed stable product revenues, reduced GAAP operating expenses, and increased cash reserves.
Collegium Pharmaceutical, Inc. announces CEO transition as Joe Ciaffoni steps down as President and CEO, effective May 24, 2024. Michael Heffernan will serve as Interim President and CEO until a successor is appointed. The Board has initiated the search for a new CEO. Collegium remains financially strong and on track to achieve its 2024 financial guidance.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.
Summary not available.
Summary not available.